Skip to content

Clinical observation of Dan-Hong Hua-Yu oral solution in treating retinal vein occlusion

Clinical observation of Dan-Hong Hua-Yu oral solution in treating retinal vein occlusion

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003100
Enrollment
Unknown
Registered
2020-03-08
Start date
2020-10-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinal vein occlusion

Interventions

Sponsors

Beijing Hospital of traditional Chinese Medicine Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Those who meet the diagnosis of traditional Chinese and western medicine RVO and have no other fundus lesions; 2. Aged between 30-65 years; 3. Patients who are within 1 month of onset and can persist in treatment for 3 months; 4. After obtaining the consent of patients and their families, the patients who voluntarily join the study;

Exclusion criteria

Exclusion criteria: 1. Patients with other ophthalmopathy affecting the evaluation of curative effect; 2. Women during pregnancy or lactation; 3. Patients who have taken hormonal drugs in the past 3 months or have been treated with this research protocol. 4. People with severe heart, liver, and kidney dysfunction and mental disorders; 5. Subjects participating in other clinical studies.

Design outcomes

Primary

MeasureTime frame
Slit lamp inspection and intraocular pressure measurement;Vision (including naked and corrected vision);

Secondary

MeasureTime frame
Traditional Chinese medicine syndrome score;

Countries

China

Contacts

Public ContactTiejun Li

Beijing Hospital of traditional Chinese Medicine Affiliated to Capital Medical University

tiejunli123@sina.com+86 18010474773

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026